Published in Ann Rheum Dis on October 11, 2010
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis (2013) 10.92
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis (2011) 1.93
Inflammatory bone loss: pathogenesis and therapeutic intervention. Nat Rev Drug Discov (2012) 1.91
Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis (2012) 1.54
Expression of FcRL4 defines a pro-inflammatory, RANKL-producing B cell subset in rheumatoid arthritis. Ann Rheum Dis (2014) 1.48
Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther (2016) 1.48
Comparing Effects of Biologic Agents in Treating Patients with Rheumatoid Arthritis: A Multiple Treatment Comparison Regression Analysis. PLoS One (2015) 1.40
Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther (2011) 1.35
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial. Ann Rheum Dis (2011) 1.31
Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. Ann Rheum Dis (2011) 1.28
Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis (2011) 1.12
[Systematic literature research for S1 guidelines on sequential medical treatment of rheumatoid arthritis]. Z Rheumatol (2012) 1.06
Efficacy of B cell depletion therapy for murine joint arthritis flare is associated with increased lymphatic flow. Arthritis Rheum (2013) 1.05
Tocilizumab in early progressive rheumatoid arthritis: FUNCTION, a randomised controlled trial. Ann Rheum Dis (2015) 1.03
Can bone loss in rheumatoid arthritis be prevented? Osteoporos Int (2013) 1.02
The pathogenesis of rheumatoid arthritis: new insights from old clinical data? Nat Rev Rheumatol (2012) 1.00
A personalized medicine approach to biologic treatment of rheumatoid arthritis: a preliminary treatment algorithm. Rheumatology (Oxford) (2011) 0.97
Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure. Biologics (2012) 0.95
Peripheral blood CD4(+)CD25(+)CD127(low) regulatory T cells are significantly increased by tocilizumab treatment in patients with rheumatoid arthritis: increase in regulatory T cells correlates with clinical response. Arthritis Res Ther (2015) 0.94
Efficacy and safety of infliximab-biosimilar compared to other biological drugs in rheumatoid arthritis: a mixed treatment comparison. Eur J Health Econ (2014) 0.92
Current and future immunomodulation strategies to restore tolerance in autoimmune diseases. Cold Spring Harb Perspect Biol (2012) 0.91
Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther (2013) 0.91
Early start and stop of biologics: has the time come? BMC Med (2014) 0.89
Effect of combination therapy on joint destruction in rheumatoid arthritis: a network meta-analysis of randomized controlled trials. PLoS One (2014) 0.89
Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial. Ann Rheum Dis (2012) 0.89
Methotrexate: optimizing the efficacy in rheumatoid arthritis. Ther Adv Musculoskelet Dis (2011) 0.88
Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology (2012) 0.88
Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int (2014) 0.84
[Recommendations for use of rituximab in patients with rheumatoid arthritis]. Z Rheumatol (2014) 0.82
Understanding the role of B cells in atherosclerosis: potential clinical implications. Expert Rev Clin Immunol (2013) 0.82
Non-tumor necrosis factor-based biologic therapies for rheumatoid arthritis: present, future, and insights into pathogenesis. Biologics (2013) 0.81
Efficacy and safety of rituximab in rheumatic diseases. Wien Med Wochenschr (2015) 0.81
Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers. Nat Rev Rheumatol (2016) 0.80
Why is there persistent disease despite biologic therapy? Importance of early intervention. Arthritis Res Ther (2014) 0.80
Bone marrow edema and osteitis in rheumatoid arthritis: the imaging perspective. Arthritis Res Ther (2012) 0.80
Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website. Rheumatol Int (2011) 0.79
Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. Arthritis Res Ther (2015) 0.78
[Combination therapy using methotrexate with DMARDs or biologics--current status]. Z Rheumatol (2011) 0.78
Methotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic review. Ann Rheum Dis (2016) 0.78
Radiological outcomes in randomized controlled trials on biologic therapies for rheumatoid arthritis: a narrative review. Clin Rheumatol (2014) 0.78
Investigation of the human FCRL1, 2, and 4 gene expressions in patients with rheumatoid arthritis. Rheumatol Int (2016) 0.77
Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review. Rheumatol Int (2016) 0.77
Combination therapy with biologic agents in rheumatic diseases: current and future prospects. Ther Adv Musculoskelet Dis (2016) 0.76
Animal Models of Bone Loss in Inflammatory Arthritis: from Cytokines in the Bench to Novel Treatments for Bone Loss in the Bedside-a Comprehensive Review. Clin Rev Allergy Immunol (2016) 0.76
Is non-biological treatment of rheumatoid arthritis as good as biologics? World J Orthop (2015) 0.76
Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate? Biologics (2012) 0.76
Correlation of Demographic and Clinical Characteristics with Rheumatoid Factor Seropositivity in Rheumatoid Arthritis Patients. Malays J Med Sci (2016) 0.75
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance. Clin Rheumatol (2012) 0.75
Rituximab for Rheumatoid Arthritis. Rheumatol Ther (2015) 0.75
Effect of concomitant statins on rituximab efficacy in patients with rheumatoid arthritis. Ann Rheum Dis (2014) 0.75
Epstein-Barr virus infection transforms CD25+ B cells into antibody-secreting cells in rheumatoid arthritis patients. Immunology (2013) 0.75
Could we use a lower dose of rituximab to treat rheumatoid arthritis in clinical practice: pros and cons? Arthritis Res Ther (2016) 0.75
Generation mechanism of RANKL(+) effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis. Arthritis Res Ther (2016) 0.75
Interleukin-6 (IL-6) Receptor Antagonist Protects Against Rheumatoid Arthritis. Med Sci Monit (2016) 0.75
Efficacy and safety of an anti-CD20 monoclonal antibody (Reditux™) for the treatment of patients with moderate to severe rheumatoid arthritis following the failure of conventional synthetic disease-modifying anti-rheumatic drugs. Clin Rheumatol (2016) 0.75
[Methotrexate]. Z Rheumatol (2016) 0.75
Rituximab in clinical practice: dosage, drug adherence, Ig levels, infections, and drug antibodies. Clin Rheumatol (2017) 0.75
Current perspective on rituximab in rheumatic diseases. Drug Des Devel Ther (2017) 0.75
Changes in forest biomass carbon storage in China between 1949 and 1998. Science (2001) 7.39
Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1. Proc Natl Acad Sci U S A (1991) 5.78
Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature (1998) 4.97
An explanation for the apparent dissociation between clinical remission and continued structural deterioration in rheumatoid arthritis. Arthritis Rheum (2008) 4.25
Graded reduction of Pafah1b1 (Lis1) activity results in neuronal migration defects and early embryonic lethality. Nat Genet (1998) 3.89
Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum (2001) 3.72
Recruitment of a ROC1-CUL1 ubiquitin ligase by Skp1 and HOS to catalyze the ubiquitination of I kappa B alpha. Mol Cell (1999) 3.58
Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann Rheum Dis (2008) 3.45
The selectins: vascular adhesion molecules. FASEB J (1995) 3.45
Cripto is required for correct orientation of the anterior-posterior axis in the mouse embryo. Nature (1998) 3.16
Presence of significant synovitis in rheumatoid arthritis patients with disease-modifying antirheumatic drug-induced clinical remission: evidence from an imaging study may explain structural progression. Arthritis Rheum (2006) 3.03
E2F-4 and E2F-5, two members of the E2F family, are expressed in the early phases of the cell cycle. Proc Natl Acad Sci U S A (1995) 2.99
An open label study of the effects of rituximab in neuromyelitis optica. Neurology (2005) 2.99
Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol (1995) 2.90
Clinical trial with inactivated hepatitis A vaccine and recommendations for its use. BMJ (1992) 2.76
Tay-sachs disease. Detection of heterozygotes and homozygotes by serum hexosaminidase assay. N Engl J Med (1970) 2.75
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression. Ann Rheum Dis (2005) 2.62
Association of heterogeneous nuclear ribonucleoprotein A1 and C proteins with reiterated AUUUA sequences. J Biol Chem (1993) 2.57
Methylation of CpG in a small region of the hMLH1 promoter invariably correlates with the absence of gene expression. Cancer Res (1999) 2.54
Conjugation of Nedd8 to CUL1 enhances the ability of the ROC1-CUL1 complex to promote ubiquitin polymerization. J Biol Chem (2000) 2.53
Mutations in the human alpha-tectorin gene cause autosomal dominant non-syndromic hearing impairment. Nat Genet (1998) 2.52
Role of the integrin alpha v beta 6 in cell attachment to fibronectin. Heterologous expression of intact and secreted forms of the receptor. J Biol Chem (1994) 2.46
Glyceraldehyde-3-phosphate dehydrogenase selectively binds AU-rich RNA in the NAD(+)-binding region (Rossmann fold). J Biol Chem (1995) 2.46
Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol). J Clin Invest (1984) 2.43
Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis (2010) 2.40
Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. Ann Rheum Dis (2008) 2.35
Targeted disruption of mouse Pds provides insight about the inner-ear defects encountered in Pendred syndrome. Hum Mol Genet (2001) 2.34
Altered lymphocyte responses and cytokine production in mice deficient in the X-linked lymphoproliferative disease gene SH2D1A/DSHP/SAP. Proc Natl Acad Sci U S A (2001) 2.29
A peripheral blood diagnostic test for acute rejection in renal transplantation. Am J Transplant (2012) 2.25
Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA. J Clin Invest (1987) 2.12
Smoking cessation in China: findings from the 1996 national prevalence survey. Tob Control (2001) 2.10
HOS, a human homolog of Slimb, forms an SCF complex with Skp1 and Cullin1 and targets the phosphorylation-dependent degradation of IkappaB and beta-catenin. Oncogene (1999) 2.05
The RING domains of the promyelocytic leukemia protein PML and the arenaviral protein Z repress translation by directly inhibiting translation initiation factor eIF4E. J Mol Biol (2001) 2.05
Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol (1993) 2.03
Kainate receptor-mediated heterosynaptic facilitation in the amygdala. Nat Neurosci (2001) 1.96
Accuracy of T2-weighted fast spin-echo MR imaging with fat saturation in detecting cartilage defects in the knee: comparison with arthroscopy in 130 patients. AJR Am J Roentgenol (1999) 1.91
[German 2012 guidelines for the sequential medical treatment of rheumatoid arthritis. Adapted EULAR recommendations and updated treatment algorithm]. Z Rheumatol (2012) 1.91
Abatacept inhibits progression of structural damage in rheumatoid arthritis: results from the long-term extension of the AIM trial. Ann Rheum Dis (2007) 1.86
Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. Ann Rheum Dis (2008) 1.84
Energy landscape of streptavidin-biotin complexes measured by atomic force microscopy. Biochemistry (2000) 1.81
Prevention of kidney ischemia/reperfusion-induced functional injury and JNK, p38, and MAPK kinase activation by remote ischemic pretreatment. J Biol Chem (2001) 1.77
Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet (1998) 1.75
The use of the GlideScope for tracheal intubation in patients with ankylosing spondylitis. Br J Anaesth (2006) 1.74
European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis (2009) 1.69
Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem (1997) 1.68
The SCF(HOS/beta-TRCP)-ROC1 E3 ubiquitin ligase utilizes two distinct domains within CUL1 for substrate targeting and ubiquitin ligation. Mol Cell Biol (2000) 1.67
B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis (2007) 1.62
Midazolam vs ondansetron for preventing postoperative nausea and vomiting: a randomised controlled trial. Anaesthesia (2007) 1.60
Clinical and molecular characterization of a rare syndrome of acute promyelocytic leukemia associated with translocation (11;17). Blood (1995) 1.58
Urocortin-1 and -2 double-deficient mice show robust anxiolytic phenotype and modified serotonergic activity in anxiety circuits. Mol Psychiatry (2009) 1.57
Reasons for outpatient referrals from generalists to specialists. J Gen Intern Med (1999) 1.55
The Akt proto-oncogene links Ras to Pak and cell survival signals. J Biol Chem (2000) 1.53
In vivo investigation of blood compatibility of titanium oxide films. J Biomed Mater Res (1998) 1.53
Trainable rule-based algorithm for the measurement of joint space width in digital radiographic images of the knee. Med Phys (2000) 1.52
When to initiate and discontinue biologic treatments for rheumatoid arthritis? J Intern Med (2011) 1.50
Modulation of AUUUA response element binding by heterogeneous nuclear ribonucleoprotein A1 in human T lymphocytes. The roles of cytoplasmic location, transcription, and phosphorylation. J Biol Chem (1997) 1.50
The RGG domain in hnRNP A2 affects subcellular localization. Exp Cell Res (2000) 1.50
Alpha-helix stabilization by natural and unnatural amino acids with alkyl side chains. Proc Natl Acad Sci U S A (1991) 1.48
The role of AHA motifs in the activator function of tomato heat stress transcription factors HsfA1 and HsfA2. Plant Cell (2000) 1.46
Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci (1987) 1.46
Difference in direct charge-parity violation between charged and neutral B meson decays. Nature (2008) 1.46
Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis (2001) 1.46
Routine use of unilateral and bilateral radial arteries for coronary artery bypass graft surgery. J Am Coll Cardiol (1996) 1.45
Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis (2010) 1.44
DNA topoisomerase I is essential in Drosophila melanogaster. Proc Natl Acad Sci U S A (1993) 1.44
Bone pain in a transplant patient. Arthritis Rheum (1997) 1.44
Enhanced stability of interleukin-2 mRNA in MLA 144 cells. Possible role of cytoplasmic AU-rich sequence-binding proteins. J Biol Chem (1994) 1.42
Identification of a novel family of targets of PYK2 related to Drosophila retinal degeneration B (rdgB) protein. Mol Cell Biol (1999) 1.41
The highly conserved COOH terminus of troponin I forms a Ca2+-modulated allosteric domain in the troponin complex. Biochemistry (2001) 1.39
Cigarette smoking among Vietnamese immigrants in California. Am J Health Promot (1995) 1.39
Cystic lesions around the knee joint: MR imaging findings. AJR Am J Roentgenol (1994) 1.38
Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis (2004) 1.38
Bridging Schwann cell transplants promote axonal regeneration from both the rostral and caudal stumps of transected adult rat spinal cord. J Neurocytol (1997) 1.37
Terrestrial gamma-ray flashes as powerful particle accelerators. Phys Rev Lett (2011) 1.35
Identification of two subtypes of infantile acid maltase deficiency. J Pediatr (2000) 1.32
Elevated synovial expression of triggering receptor expressed on myeloid cells 1 in patients with septic arthritis or rheumatoid arthritis. Ann Rheum Dis (2008) 1.31
MR arthrographic depiction of tears of the rotator cuff: benefit of abduction and external rotation of the arm. Radiology (1994) 1.30
Premorbid prevalence of ADHD and development of secondary ADHD after closed head injury. J Am Acad Child Adolesc Psychiatry (1998) 1.30
Prevalence and significance of acquired immunodeficiency syndrome-related retinal microvasculopathy. Am J Ophthalmol (1989) 1.29
Characterization of a novel human serine protease that has extensive homology to bacterial heat shock endoprotease HtrA and is regulated by kidney ischemia. J Biol Chem (2000) 1.27
Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol (2005) 1.27
Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. Mol Psychiatry (2008) 1.25
The immunobiology of vitamin D. Immunol Today (1988) 1.25
Impaired fertility in mice deficient for the testicular germ-cell protease PC4. Proc Natl Acad Sci U S A (1997) 1.24
PDGF stimulates the massive expansion of glial progenitors in the neonatal forebrain. Glia (2009) 1.24
Mucin gene expression in colonic tissues and cell lines. Cancer Res (1992) 1.24
Expression of MUC2 and MUC3 mRNA in human normal, malignant, and inflammatory intestinal tissues. J Histochem Cytochem (1996) 1.24
Cancer symptom control: feasibility of a tailored, interactive computerized program for patients. Fam Community Health (2001) 1.23
Association of glenoid labral cysts with labral tears and glenohumeral instability: radiologic findings and clinical significance. Radiology (1994) 1.22
Intraoperative brachytherapy following thoracoscopic wedge resection of stage I lung cancer. Chest (1998) 1.22
Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides. J Med Chem (2001) 1.21
[Strategies for improved healthcare of people with the endemic disease rheumatism exemplified by rheumatoid arthritis]. Z Rheumatol (2011) 1.21
Prolonged and site-specific over-expression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol Psychiatry (2010) 1.20
Conformational modulation of slow skeletal muscle troponin T by an NH(2)-terminal metal-binding extension. Am J Physiol Cell Physiol (2000) 1.20
hnRNP A2 and hnRNP L bind the 3'UTR of glucose transporter 1 mRNA and exist as a complex in vivo. Biochem Biophys Res Commun (1999) 1.19